---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-011597"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2026-04-07T23:59:59+00:00"
generated_at: "2026-05-15T06:58:21.165339+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CervoMed presents neflamapimod Phase 3 design and MRI data at LBD Annual Meeting

## Summary
- New MRI analyses from Phase 2b RewinD-LB trial show neflamapimod may reduce basal forebrain atrophy in DLB.
- Global regulatory alignment achieved; Phase 3 trial design finalized.
- Plasma GFAP biomarker correlates with cognitive decline and is responsive to neflamapimod treatment.
- Additional MRI data to be presented at AAN Annual Meeting on April 22, 2026.
- No approved treatments for DLB in US or EU; neflamapimod aims to be first.

## SEC filing metadata
- accession: 0001437749-26-011597
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2026-04-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774926011597/0001437749-26-011597-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774926011597/crvo20260407_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-011597
- JSON: https://secwatch.observer/filing/0001437749-26-011597.json
- Plain text: https://secwatch.observer/filing/0001437749-26-011597.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.